Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS‐1 monotherapy trial

Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)

(2023) Clare J Lee et al.   Journal of the Endocrine Society

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

(2022) John P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

(2021) Domenica Rubino et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

(2021) Julio Rosenstock et al.   LANCET

EADSG Guidelines: Insulin Therapy in Diabetes

(2018) Bahendeka Silver et al.   Diabetes Therapy

EADSG Guidelines: Insulin Therapy in Diabetes

(2018) Bahendeka Silver et al.   Diabetes Therapy